Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin and Linagliptin in Pediatric T2DM (DINAMO)
NCT03429543Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2018
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of empagliflozin, linagliptin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Started Mar 2018; status: completed.
02
Drugs
empagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03429543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03429543.